Idorsia Launches Pivlaz (clazosentan) for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Japan
Shots:
- The company reported the commercial availability of clazosentan based on the 2 P-III studies in a ratio (1:1) in patients with post-aSAH for 15 days at 57 neurosurgical centers in Japan
- In both studies, the therapy showed a reduction in the occurrence of cerebral vasospasm-related morbidity & all-cause mortality events by >50% within 6wks. In the pooled analysis of 2EPs, 60% reduction in vasospasm-related DIND & 55% in vasospasm-related new cerebral infarcts, was well tolerated with no unexpected safety findings
- Pivlaz (150mg) is a potent, selective ETA receptor antagonist & is indicated for cerebral vasospasm, vasospasm-related cerebral infarction & cerebral ischemic symptoms after aSAH securing
Ref: Idorsia | Image: Idorsia
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
